Clinical Trial Update: A Study of Lirentelimab (AK002) in Patients With Active Eosinophilic Duodenitis [Phase 3]

View source ↗

Summary

Phase 3 trial of lirentelimab (AK002) in active eosinophilic duodenitis and eosinophilic gastroenteritis has completed with results posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Eosinophilic Duodenitis
• Eosinophilic Gastroenteritis

Drugs mentioned

• lirentelimab (lirentelimab)

Snippet

Sponsor: Allakos Inc. | Conditions: Eosinophilic Duodenitis, Eosinophilic Gastroenteritis | Phase 3 | Status: COMPLETED | Results posted: 2024-01-02